Intermountain Medical Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2007
NCT00454818
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Intermountain Medical Center | Intermountain Medical Center, Murray, UT

Active Ingredients

Drugs in Phase 2 Trials (2)

mydicar (1 trial)

ranolazine (ranexa) (1 trial)

Drugs in Other Trials (2)

umbilical cord mesenchymal stem cells (1 trial)

vitis vinifera (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Heart Failure (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4